How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

In today’s episode, we had the pleasure of speaking with Rory Shallis, MD, an assistant professor of medicine and hematology at Yale School of Medicine, part of Yale New Haven Health in Connecticut.

Shallis sat down with us to share some of the research that has been generated in myelodysplastic syndrome (MDS) over the past year or so, touching on the evolution of clinical trial end points and where the field is headed in terms of therapeutic classes. He also spoke to the investigation of the late-stage erythroid maturation agent luspatercept-aamt (Reblozyl) in this population in the phase 3 ELEMENT-MDS (NCT05949684) and MAXILUS (NCT06045689) trials.

In our exclusive interview, Shallis discussed the research basis for the ELEMENT-MDS trial in MDS, the potential of intervening with luspatercept before patients become red blood cell transfusion dependent, and aspects of the trial to be aware of for patient enrollment.